U.S. biotechnology group Amgen has agreed to buy unlisted
Decode Genetics , a pioneer in hunting down genes linked to disease, for $415 million in cash, writes Reuters. Amgen and Decode said on Monday that the transaction did not require regulatory ...
[Published PE Hub News - Dec 11 2012]